OncoSil Medical (ASX:OSL) announced early clinical results from Ankara Bilkent City Hospital in Türkiye, demonstrating a potential paradigm shift in the treatment of unresectable locally advanced pancreatic cancer.
In a clinical setting, an unprecedented 83% of patients treated with the OncoSil device alongside standard-of-care chemotherapy underwent surgical resection with curative intent.
The figure outperforms historical benchmarks, which typically report resection rates between 13% and 26% for patients receiving chemotherapy alone.
The OncoSil device is a localised brachytherapy tool that delivers a targeted dose of beta radiation directly into the tumour.
In the Turkish study, post-treatment analysis of the six treated patients showed high therapeutic efficacy: one patient achieved a complete response, four achieved partial responses, and one remained stable.